Takeda wins priority review for $400M colorectal cancer drug, licensed from Hutchmed in January
Takeda and Hutchmed scored a priority review Thursday afternoon for a colorectal cancer drug, the companies announced.
The experimental drug in question is fruquintinib, previously approved in China in 2018 to treat metastatic colorectal cancer. Takeda and Hutchmed are aiming to bring fruquintinib to the US and other countries outside China in the same indication, and the FDA set its decision date for Nov. 30 of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.